• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA closes out CryoLife warning letter, PerClot trial launches

FDA closes out CryoLife warning letter, PerClot trial launches

April 28, 2015 By Brad Perriello

FDA closes out CryoLife warning letter, PerClot trial launches

UPDATE April 28, 2015, with Q1 earnings results.

CryoLife Inc. (NYSE:CRY) said yesterday that the FDA closed out a warning letter from 2013 about problems at a plant in Kennesaw, Ga., after follow-up inspections last month found the issues corrected and no further violations.

The FDA’s website lists the close-out date as April 23 for the January 29, 2013, warning letter.

"Resolving the FDA warning letter was my top priority when I joined the company. I am pleased that we passed the recent FDA re-inspection with no 483 observations and that the FDA has lifted our warning letter. The CryoLife team did a great job responding to the FDA’s concerns, and we are committed to the continued enhancement of our quality systems and delivery of the highest quality products to patients," chairman, president & CEO Pat Mackin said in prepared remarks.

Atlanta-based CryoLife also said it launched a clinical trial of its PerClot surgical hemostasis powder, enrolling the 1st patient under an investigational device exemption from the FDA, and reported its 1st-quarter results.

The 324-patient PerClot IDE study is a multicenter, multidisciplinary, controlled clinical investigation designed to compare the safety and efficacy of PerClot with C.R. Bard‘s (NYSE:BCR) Arista MPH hemostat "in multiple surgical disciplines when used as an adjunct to conventional means of achieving hemostasis such as pressure or ligature," CryoLife said.

The primary efficacy endpoint is achievement of hemostasis at the site of application at 7 minutes following application, with a secondary efficacy endpoint of hemostasis at the site of application at 5 minutes. Safety endpoints include the incidence of reoperation due to bleeding, total hospitalization and procedure time and the incidence of procedure complications and/or adverse events at 3 months, the company said.

"The first patient enrolled in the PerClot IDE clinical trial is a positive milestone for the company and our strategy to expand indications for our products," Mackin said in a prepared statement. "We will be working to bring other trial sites online in the coming months, positioning us to complete enrollment in the trial in the 1st half of 2016.  With a 3-month follow-up period, we would anticipate obtaining FDA approval for PerClot in the 2nd half of 2017."

CryoLife and Bard are locked in a battle over the topical version of PerClot and the Arista product. Bard last month won a preliminary injunction barring U.S. sales of PerClot Topical in a patent infringement battle over the hemostatic agents.

Q1 sales, earnings off, but earnings outlook raised

CryoLife posted a swing to 1st-quarter losses and missed top-line expectations with a -5.3% sales slide during the 3 months ended March 31. The company reported losses of -$274,000, or -1¢ per share, on sales of $33.8 million, compared with Q1 2014 profits of $1.1 million. Analysts on Wall Street were looking for break-even on sales of $36.6 million.

The company said it now expects to break even this year, compared with prior guidance of -3¢ to 0¢, but cut its top-line forecast to sales growth of 3% to 4%, or $148.5 million to $150.5 million. That’s down from growth of 4% to 6%, or $151.0 million to $153.0 million.

The raised earnings outlook and FDA news buoyed CRY shares, lifting them 3.8% to $10.37 apiece today in early-afternoon activity.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Surgical Tagged With: C.R. Bard, Clinical Trials, CryoLife, Warning Letter

More recent news

  • Zimmer Biomet to expand robotic suite with Monogram acquisition
  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy